Skip to content
OpenCapital
Get started

Xilio Therapeutics, Inc. XLO Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$12.7MBeat by $4.1MDiluted EPS-$0.58Beat by $0.08
Revenue estimate$8.5M
EPS estimate-$0.66

Next report

Aug 13, 2026 (in a month)
Revenue estimate$12.7M
EPS estimate-$0.59

Versus estimates

Revenue

Q1 2026$12.7MBeat by $4.1M
Q4 2025$13.7MBeat by $2.8MQ3 2025$19.1MBeat by $431.0KQ2 2025$8.1MMiss by $10.6MQ1 2025$2.9MMiss by $20.3MQ4 2024$1.7MMiss by $21.5M

Diluted EPS

Q1 2026-$0.58Beat by $0.08
Q4 2025-$0.85Beat by $0.83Q3 2025-$0.03Beat by $0.42Q2 2025-$0.16Beat by $0.94Q1 2025-$0.18Beat by $2.52Q4 2024-$0.20Beat by $2.83

Ask the moment Xilio Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Xilio Therapeutics, Inc. report Q1 2026 earnings?
Xilio Therapeutics, Inc. (XLO) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Xilio Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Xilio Therapeutics, Inc. reported revenue of $12.7M and diluted EPS of $-0.58 for Q1 2026.
Did Xilio Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $8.5M by $4.1M. EPS beat the consensus estimate of $-0.66 by $0.08.
How did Xilio Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 331.7% from $2.9M a year earlier and diluted EPS declined 222.2% from $-0.18.
Where can I find Xilio Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-218194) and the 10-Q periodic report (0001193125-26-218200) directly on SEC EDGAR. The filing index links above go to sec.gov.